title: Use of LDH and autoimmune side effects to predict response to ipilimumab treatment.
abstract: Ipilimumab is a cytotoxic T-lymphocyte antigen-4 antibody that enhances T-cell activity and proliferation.
  
  
  
  In a retrospective analysis of 86 patients the clinical benefits of ipilimumab treatment were correlated with laboratory and clinical data.
  
  
  
  A lactate dehydrogenase (LDH) value within the normal range before the start of therapy was significantly correlated with better OS (p ≤ 0.009). An increase in LDH level after two cycles was indicative of a poor outcome, and was significantly negatively correlated with treatment response and overall survival and progression-free survival. 42% of all patients suffered from autoimmune toxicity (CTCAE grades 2-4). The occurrence of autoimmune toxicity clearly correlated with clinical benefit.
  
  
  
  Changes in LDH level and side effects correlate with response to therapy and survival.
authors.affiliation: Department of Dermatology & National Centre for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Dick
authors.affiliation: Department of Dermatology & National Centre for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
authors.forename: N
authors.initials: N
authors.lastname: Lang
authors.affiliation: German Cancer Research Centre DKFZ, Department of Biostatistics, Heidelberg, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Slynko
authors.affiliation: German Cancer Research Centre DKFZ, Department of Biostatistics, Heidelberg, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Kopp-Schneider
authors.affiliation: Department of Dermatology & National Centre for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
authors.forename: C
authors.initials: C
authors.lastname: Schulz
authors.affiliation: Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Centre Heidelberg, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Dimitrakopoulou-Strauss
authors.affiliation: Department of Dermatology & National Centre for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
authors.forename: A H
authors.initials: AH
authors.lastname: Enk
authors.affiliation: Department of Dermatology & National Centre for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany.
authors.forename: J C
authors.initials: JC
authors.lastname: Hassel
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000175:diagnosis* / Q000401:mortality; D054316:Biomarkers, Pharmacological / Q000378:metabolism; D002097:C-Reactive Protein / Q000378:metabolism; D060908:CTLA-4 Antigen / Q000276:immunology; D049109:Cell Proliferation; D064420:Drug-Related Side Effects and Adverse Reactions / Q000175:diagnosis* / Q000401:mortality; D005260:Female; D006801:Humans; D000074324:Ipilimumab; D007770:L-Lactate Dehydrogenase / Q000378:metabolism*; D008213:Lymphocyte Activation; D008297:Male; D008545:Melanoma / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000401:mortality; D016019:Survival Analysis; D013601:T-Lymphocytes / Q000276:immunology*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D054316:Biomarkers, Pharmacological; D060908:CTLA-4 Antigen; D000074324:Ipilimumab; D002097:C-Reactive Protein; D007770:L-Lactate Dehydrogenase
keywords: LDH; autoimmune side effects; ipilimumab; melanoma